Pacific Edge raises $20.7m in successful capital

Cancer diagnostics company, Pacific Edge, has announced a successful capital raise of $20.7 million.

The capital raise consisted of a $15m placement and a $5m share purchase plan (SPP).

The SPP, which closed on July 31, 2025, received subscriptions for approximately $4.7m of new ordinary shares.

As a result, the company's directors have decided to accept all eligible SPP applications in full.

The placement was upsized after the directors resolved to accept oversubscriptions.

However, the placement is conditional on shareholder approval, which will be sought at the annual shareholders' meeting on August 6, 2025.

The issue of shares under the SPP is also dependent on the placement becoming unconditional.

If these conditions are met, 207,350,411 new shares will be issued at $0.10 per share.

The company expects the allotment of shares and commencement of trading on the NZX to take place on August 13, 2025.